Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease

Description

Preclinical studies have demonstrated that high mechanical index (MI) impulses from a diagnostic ultrasound (DUS) transducer during an intravenous microbubble infusion (sonothrombolysis) can restore epicardial and microvascular flow in acute ST-segment elevation myocardial infarction (STEMI). The investigators propose to demonstrate the clinical effectiveness of sonothrombolysis in multiple centers and in a wide scenario of acute coronary syndromes.

Conditions

Acute Myocardial Infarction, Unstable Angina

Talk to us

Study Overview

On this page

Study Details

Study overview

Preclinical studies have demonstrated that high mechanical index (MI) impulses from a diagnostic ultrasound (DUS) transducer during an intravenous microbubble infusion (sonothrombolysis) can restore epicardial and microvascular flow in acute ST-segment elevation myocardial infarction (STEMI). The investigators propose to demonstrate the clinical effectiveness of sonothrombolysis in multiple centers and in a wide scenario of acute coronary syndromes.

High Ultrasound Mechanical Index and MicrobuBBLEs to Reduce Acute Myocardial Infarction Burden I

Therapeutic Use of Contrast Ultrasound in Acute Coronary Artery Disease

Condition
Acute Myocardial Infarction
Intervention / Treatment

-

Contacts and Locations

Omaha

Department of Internal Medicine, Division of Cardiovascular Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States, 68198

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Age ≥30 years with STEMI with less than 12 hours of chest pain onset.
  • * Age ≥30 years with STEMI initially treated in a primary setting by fibrinolytic therapy within 12h
  • * Age ≥30 years with NSTEMI with high-risk unstable angina who will undergo elective PCI
  • * Eligible for emergent PCI therapy.
  • * No contraindications or hypersensitivities to ultrasound contrast agents
  • * Known or suspected hypersensitivity to ultrasound contrast agent used for the study.
  • * Cardiogenic Shock.
  • * Life expectancy of less than two months or terminally ill.
  • * Known bleeding diathesis or contraindication to glycoprotein 2b/3a inhibitors, anticoagulants, or aspirin.
  • * Known large right to left intracardiac shunts or severe pulmonary hypertension.
  • * Patients who received thrombolytic therapy previously to enrollment.
  • * Women of childbearing potential.

Ages Eligible for Study

30 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Sao Paulo General Hospital,

Wilson Mathias Jr, MD, PhD, PRINCIPAL_INVESTIGATOR, Heart Institute - University of São Paulo Medical School

Jeane Tsutsui, MD, PhD, PRINCIPAL_INVESTIGATOR, Heart Institute - University of São Paulo Medical School

Thomas R Porter, MD, PRINCIPAL_INVESTIGATOR, University of Nebraska Medical Center, Omaha, NE

Study Record Dates

2026-02-01